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doi:10.1Objective: Animal and human myocytes demonstrate significant swelling and reduced contractility during ex-
posure to stress (metabolic inhibition, hyposmotic stress, or hyperkalemic cardioplegia), and these detrimental
consequences may be inhibited by the addition of diazoxide (adenosine triphosphate-sensitive potassium channel
opener) via an unknown mechanism. Both SUR1 and SUR2A subunits have been localized to the heart, and
mouse sarcolemmal adenosine triphosphate-sensitive potassium channels are composed of SUR2A/Kir6.2 sub-
units in the ventricle and SUR1/Kir6.2 subunits in the atria. This study was performed to localize the mechanism
of diazoxide by direct probing of sarcolemmal adenosine triphosphate-sensitive potassium channel current and by
genetic deletion of channel subunits.
Methods: Sarcolemmal adenosine triphosphate-sensitive potassium channel current was recorded in isolated
wild-type ventricular mouse myocytes during exposure to Tyrode’s solution, Tyrode’sþ100 mmol/L diazoxide,
hyperkalemic cardioplegia, cardioplegiaþdiazoxide, cardioplegiaþ100 mmol/L pinacidil, or metabolic inhibition
using whole-cell voltage clamp (N ¼ 7–12 cells per group). Ventricular myocyte volume was measured from
SUR1(-/-) and wild-type mice during exposure to control solution, hyperkalemic cardioplegia, or
cardioplegiaþ100 mmol/L diazoxide (N ¼ 7–10 cells per group).
Results: Diazoxide did not increase sarcolemmal adenosine triphosphate-sensitive potassium current in wild-
type myocytes, although they demonstrated significant swelling during exposure to cardioplegia that was pre-
vented by diazoxide. SUR1(-/-) myocytes also demonstrated significant swelling during exposure to cardioplegia,
but this was not altered by diazoxide.
Conclusions: Diazoxide does not open the ventricular sarcolemmal adenosine triphosphate-sensitive potassium
channel but provides volume homeostasis via an SUR1-dependent pathway in mouse ventricular myocytes,
supporting a mechanism of action distinct from sarcolemmal adenosine triphosphate-sensitive potassium channel
activation. (J Thorac Cardiovasc Surg 2010;140:1153-9)The adenosine triphosphate-sensitive potassium (KATP)
channel opener diazoxide (DZX) is cardioprotective and
mimics ischemic preconditioning in animal models.1 We
previously documented significant swelling of isolated
myocytes and associated reduced contractility secondary
to exposure to standard hypothermic hyperkalemic cardio-
plegia (CPG) solution in human and other species.2,3
These detrimental consequences were ameliorated by the
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Sopener, we hypothesized that KATP channels may play
a role in myocyte volume homeostasis and that myocyte
swelling may be one mechanism of myocardial stunning.4
Myocyte swelling and reduced contractility are also
observed after exposure to hyposmotic and ischemic
stress.4,5 Notably, DZX ameliorates both the structural and
functional derangements secondary to all 3 stresses:
hyperkalemic CPG, mild hyposmotic stress, and ischemic
stress.2-5 The addition of 5-hydroxydecanoate, a claimed
mitochondrial KATP (mKATP) channel blocker, or HMR
1098, a claimed sarcolemmal KATP (sKATP) channel
blocker, to ischemic stress and hyperkalemic CPG did not
alter the beneficial observations noted with DZX alone.2,4
The cardioprotective mechanism of DZX remains unknown.
DZX has been described as an mKATP channel opener,
with ‘‘selectivity’’ toward the mKATP channel and only
weak sKATP channel activation at high doses.
6 However,
controversy regarding the specificity of KATP channel
openers and blockers suggests that pharmacologicmanipula-
tion of theKATP channel, using potassium channel openers or
sulfonylurea receptor (SUR) blockers, may be inadequate to
definitively confirm ion flux across the sKATP channel,
7-9 and
it remains unclear whether DZX provides cardioprotectiondiovascular Surgery c Volume 140, Number 5 1153
Abbreviations and Acronyms
CPG ¼ cardioplegia
DZX ¼ diazoxide
KATP ¼ adenosine triphosphate-sensitive
potassium
KO ¼ knockout
MI ¼ metabolic inhibition
mKATP ¼ mitochondrial KATP
NT ¼ normal Tyrode’s solution
sKATP ¼ sarcolemmal KATP
SUR ¼ sulfonylurea receptor
WT ¼ wild-type
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Svia the sKATP channel, the mKATP channel, or a KATP
channel-independent mechanism.
KATP channels are composed of a Kir inward rectifier
channel-forming subunit and a sulfonylurea sensitive regu-
latory subunit, SUR (Figure 1).10 It is clear that sKATP chan-
nels require both Kir6.2 and SUR2A subunits in the
ventricle, but Kir6.2 and SUR1 in the atria.11 Both SUR1
and SUR2A are expressed in mouse heart,11,12 and there is
evidence that SUR2 and SUR1 subtypes are both present
in cultured neonatal rat ventricular myocytes.13 Mice lack-
ing the SUR1 subunit seem to tolerate ischemia/reperfusion
injury better than wild-type (WT) mice in a model of left an-
terior descending coronary artery ligation.12 Although there
is some evidence for SUR1 subunits in the ventricle of var-
ious species, KATP currents in mouse ventricle are unaltered
in mice lacking the SUR1 subunit.11
We initially hypothesized that the mechanism of action of
DZX might involve opening the sKATP channel (SUR2A/
Kir6.2). Previous work documented a beneficial effect of
KATP channel opener DZX in ventricular myocytes that
was unaltered by the pharmacologic inhibition of the KATP
channel.2,4 The first part of this study was designed to
definitively investigate the action of DZX by the direct
measurement of sKATP channel current in WT mice using
whole-cell voltage clamp.
After demonstrating that sKATP (SUR2A/Kir6.2) channel
activity was not observed in ventricular myocytes from WT
mice during exposure to DZX, and knowing that SUR1 sub-
units have been documented in ventricular tissue,11-13 we next
hypothesized that DZX might act via SUR1 subunits of an
alternative KATP channel or some other channel in
ventricular cells. The second part of this study was therefore
designed to determine whether ventricular myocytes lacking
the SUR1 subunit would be responsive to DZX during stress.
This study was designed to elucidate the location of action
of DZX by the directmeasurement of sKATP channel activity
(in WT mice) and by response to stress in ventricular
myocytes from WT mice and mice lacking the SUR1 sub-1154 The Journal of Thoracic and Cardiovascular Surunit. The elucidation of DZX’s mechanism of action in
this model will facilitate its future clinical use.
MATERIALS AND METHODS
Myocyte Isolation
All animal procedureswere approved by theAnimal Studies Committee at
WashingtonUniversity School ofMedicine, and all animals received humane
care in compliance with the ‘‘Guide to Care andUse of LaboratoryAnimals.’’
Ventricular myocytes were used for all experiments and isolated from
adult mice (either WT or SUR1 knockout [KO], either sex, 6 weeks to 5
months, 25–30 g body weight) as previously described.14 Rapid cardiec-
tomy was performed in the anesthetized (2.5% tribromoethanol [Avertin;
Sigma, St. Louis, Mo]) mouse, and the aorta was cannulated using
a 28-gauge needle. The heart was attached to a Langendorff apparatus,
and solution A was perfused through the aorta for 5 minutes. The heart
was then perfused at 37C for 12 minutes with solution B. The left ventricle
was removed and transferred into solution C, where it was gently dispersed
by glass pipette at room temperature. The cells were allowed to centrifuge
by gravity, and serial washings were performed every 10 minutes for
a 30-minute period. Cells were used in experiments within 5 hours after
isolation. A typical yield of viable myocytes was 65% to 75% per mouse.
SolutionA consisted of (inmillimoles per liter, except as noted) 116NaCl;
5.36KCl; 0.97Na2HPO4; 1.47KH2PO4; 21.10HEPES; 11.65 glucose; 26.50
mmol/L phenol red (Sigma); 3.72 MgCl2; 4.40 NaHCO3; essential vitamins
(1003, 10 mL; GIBCO, Grand Island, NY); and amino acids (503, 20 mL;
GIBCO). Solution B consisted of solution A plus 10 mmol/L CaCl2 and
1.2 mg/mL collagenase (Type 2; Worthington Biochemical Corporation,
Freehold, NJ). Solution C consisted of solutionA plus 5mg/mL bovine serum
albumin (Sigma), 1.25 mg/mL taurine, and 150 mmol/L CaCl2.
The DZX (7-chloro-3-methyl-1,2,4-benzothiadiazine-1,1-dioxide;
Sigma) dose of 100 mmol/L was used because it was effective in ameliorat-
ing cell swelling secondary to stress (hyperkalemic CPG, hyposmotic stress,
and metabolic inhibition [MI]) in previous studies.2-5 A stock solution of
DZX was made by dissolving the reagent in 0.1% dimethyl sulfoxide, at
which concentration dimethyl sulfoxide has no effect on cell volume.15
Cells were selected for viability using the following criteria: normal rod
shape, smooth edges, sharp borders and clear striations, absence of vacuoles
or blebbing, and lack of spontaneous beating.15 After isolation, acceptable
myocytes were randomly assigned to a test solution group. A maximum of
2 cells were used per each animal.
Electrophysiology in Wild-Type Myocytes
After isolation, WT myocytes were placed in a recording chamber con-
taining normal Tyrode’s solution (NT). Macroscopic currents in isolated ven-
tricular myocytes were recorded using standard whole-cell voltage-clamp
recording techniques.16 Patch-clamp electrodes (1–3 MU when filled with
electrode solution) were fabricated from soda lime glass microhematocrit
tubes (Kimble 73813, Kimble Glass Co, Vineland, NJ). Electrode solution
contained the following (in millimoles/liter): 140 KCl, 10 HEPES, and 10
EGTA (pH 7.3–7.4). Cell capacitance and series resistance were determined
using a 5- to 10-mV hyperpolarizing square pulse from a holding potential of
70 mV after establishment of the whole cell recording configuration.
PClamp 9.2 software and DigiData 1322 (both fromMolecular Devices, Sun-
nyvale, Calif) were used to generate command pulses and collect data. Data
were filtered at 5 kHz. A 4-second ramp from110 and 40 mV was used to
isolate and detect sKATP channel current only.
17
Experimental protocol
IsolatedWTmyocytes were exposed to NT for baseline measurement for
1 to 2 minutes, followed by exposure to test solution (5–10 minutes), and
followed by NT for 5 to 10 minutes. Test solutions included NT (n ¼ 8
cells), NT þ 100 mmol/L DZX (n ¼ 7 cells), hyperkalemic CPG in the
form of St Thomas’ solution (CPG, Plegisol, Abbott Laboratories, Northgery c November 2010
FIGURE 1. Composition of the sKATP channel and location of various subunits in various tissues. The channel is a functional octamer of 4 Kir6.x subunits
(generating the channel pore) and 4 SUR subunits that generate the regulatory subunit. TMD,Transmembrane domain;NBF, nucleotide-binding fold;M1,M2,
transmembrane helices.
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SChicago, Ill) (n ¼ 11 cells), CPGþ100 mmol/L DZX (n ¼ 8 cells), CPGþ
100 mmol/L pinacidil (Sigma) (n¼ 12 cells), and MI (n ¼ 8 cells). NT con-
sisted of the following (in millimoles/liter): 137 NaCl, 5.4 KCl, 25
NaH2PO4, 10 glucose, 0.5 MgCl2, 5 HEPES, and 3 NaHCO3 (pH 7.3–
7.4). St Thomas’ solution consisted of (in millimoles/liter) 110 NaCl, 10
NaHCO3, 16 KCl, 32 MgCl2, and 2.4 CaCl2, and was equilibrated with
95% O2 5% CO2 and titrated to correct to pH 7.3. MI solution consisted
of (in millimoles/liter) 137 NaCl, 5.4 KCl, 3 NaHCO3, 0.16 NaH2PO4, 10
2-deoxyglucose, 0.5 MgCl2, 5 HEPES, 5% oligomycin, and 3 NaHCO3
(pH 7.3–7.4). Isolated sKATP channel activity and cellular capacitance
were recorded during exposure to NT and compared with channel activity
during test solution exposure.
MI was used as a positive control to document an increase in sKATP chan-
nel current. Myocytes that demonstrated an increase in potassium current
were subsequently exposed to glibenclamide (10 mmol/L, a known sKATP
channel blocker; Sigma) to confirm that the increase in potassium current
during exposure to MI was through sKATP channels.
Myocyte Volume Imaging in Wild-Type and SUR1
(-/-) Myocytes
An aliquot of isolated myocytes was placed in a glass-bottomed chamber
on an inverted microscope stage (Leitz, Wetzlar, Germany) equipped with
Hoffman modulation optics (Modulation Optics, Greenvale, NY). After
a 5-minute stabilization period, the chamber was perfused at a rate of 3
mL/min with 37C NT (in millimoles/liter) 130 NaCl, 5 KCl, 2.5 CaCl2,
1.2 MgSO4, 24 NaHCO3, 1.75 Na2HPO4, and 10 glucose, buffered to
a pH of 7.4 using 95% O2–5% CO2. Chamber temperature was controlled
by a waterbath system (Thermo Haake, Karlsruhe, Germany). Cell imagesThe Journal of Thoracic and Carwere displayed on a video monitor using a charge-coupled device camera
(KPM1U; Hitachi Denshi, Tokyo, Japan). Digital images of cells were cap-
tured at a rate of 120 frames per second using a video-frame grabber (Scion
Corp, Frederick, Md) and manually traced using Scion Image software
(Scion Corp). Length, width, and area were measured and recorded. To cal-
culate cell volume, it was assumed that changes in cell width and thickness
were proportional, and relative cell volume change was determined by the
following formula:15
volumet=volumec ¼ ðareat 3 widthtÞ=ðareac 3 widthcÞ
where t and c refer to test and control, respectively. On the basis of repeated
measurements of single images and measurements of multiple images of
a cell, this methodology for estimating cell volume has been shown to be
reproducible with an error of less than 1%.15
SUR1(-/-) mice were created by removal of the 1-kbp gene segment con-
taining both promoter and exon 1 sequences of SUR1 gene by re-mediated
recombination.18 Genotype was confirmed by polymerase chain reaction
analysis.18 This deletion is not lethal, and the SUR1 (-/-) mice lack pancre-
atic b cell KATP channels (SUR1/Kir6.2) and glucose-stimulated insulin
secretion, and are mildly glucose intolerant.18
Experimental protocol
Myocytes were not subjected to ischemia or modified ischemia in this
protocol to delineate changes caused by the stress of exposure to CPG alone.
Myocytes fromWT andKOmicewere perfusedwith 37CNT for 5minutes
to obtain baseline measurements. Any baseline changes in cell volume sec-
ondary to the isolation or imaging protocol would be evident during this pe-
riod.Myocytes were then perfused for 5 minutes with test solution, followeddiovascular Surgery c Volume 140, Number 5 1155
FIGURE 2. A, DZX does not elicit sarcolemmal adenosine triphosphate-
sensitive potassium current in WT myocytes. The y-axis represents
potassium current (nA), and the x-axis represents time. WT myocytes
were initially exposed to NT for baseline potassium current measurement,
followed by test solution and reexposure to NT. The first graph (far left)
is a representative cell exposed to NT throughout the experiment. The sec-
ond graph (middle) is a representative cell exposed to NT with DZX during
the test period. The addition of DZX to NT did not alter the potassium cur-
rent. The third graph (far right) is a representative cell exposed to NT fol-
lowed by MI. MI was associated with an increase in potassium current
that was reversed by the addition of glibenclamide. B, DZX does not elicit
sKATP current in WTmyocytes. Cell conductance is represented in nanosei-
mens/picofarads (y axis) and the test solution on the x-axis. Test solutions
included NT in addition to DZX and MI. When correcting for cell conduc-
tance, there was a significant increase in potassium current in cells exposed
to MI (*P ¼ .002 vs NT). DZX, Diazoxide; MI, metabolic inhibition; NT,
normal Tyrode’s solution; N, number of myocytes; GLIB, glibenclamide.
FIGURE 3. A, Pinacidil elicits an increase in adenosine triphosphate-
sensitive potassium current in WT cells exposed to CPG, whereas DZX
does not. The y-axis represents potassium current (nA), and the x-axis rep-
resents time. WT myocytes were initially exposed to NT for baseline potas-
sium current measurement, followed by test solution and reexposure to NT.
The first graph (far left) is a representative cell exposed to hyperkalemic
CPG (St Thomas solution) alone during the test period. The second graph
(middle) is a representative cell exposed to CPG with DZX during the test
period. The third graph (far right) is a representative cell exposed to CPG
with pinacidil during the test period. The addition of pinacidil to CPG in-
duced potassium current. B, Pinacidil elicits an increase in KATP current
in WT cells exposed to CPG, whereas DZX does not. Cell conductance is
represented in nanoseimens/picofarads (y-axis) and test solution on the x-
axis. Test solutions included hyperkalemic CPG (St Thomas solution),
CPG with DZX, and CPG with pinacidil. When correcting for cell conduc-
tance, there was a significant increase in potassium current in cells exposed
to pinacidil supplemented CPG (*P ¼ .025 vs CPG). CPG, Cardioplegia;
DZX, diazoxide; PIN, pinacidil; N, number of myocytes; NT, normal
Tyrode’s solution; PIN, pinacidil.
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Sby a 5-minute reexposure period to 37C NT. Test solutions included NT
(n ¼ 8 cells for KO; n ¼ 7 cells for WT), hyperkalemic CPG in the form
of St Thomas’ solution (n ¼ 10 cells for KO; n ¼ 7 cells for WT), or
CPGþ100 mmol/L DZX (n¼ 8 cells for KO; n ¼ 7 cells for WT). Volume
measurements were made after the end of each 5-minute period.
Statistical Analysis
Data were analyzed using SYSTAT 11 (SYSTAT Software Inc, Point
Richmond, Calif). All data are presented as mean value  standard error
of the mean, with N equal to the number of cells in each group. For cell vol-
ume measurements, a repeated-measures analysis of variance was used for
sequential time-based measurements for each test solution against its own
baseline value. By using Fisher’s least significant difference test, post hoc
multiple comparisons between different test groups were made separately
during the test solution and reexposure periods. For electrophysiology
experiments, Student t test was used to compare data.
RESULTS
Sarcolemmal KATP Channel Current in Wild-Type
Myocytes
WT ventricular myocytes exposed to NT exhibited no
increase in sarcolemmal adenosine triphosphate-sensitive1156 The Journal of Thoracic and Cardiovascular Surpotassium current throughout the experiment (Figure 2, A),
and the addition of DZX to NT was not associated with an
increase in potassium current (Figure 2, A). sKATP current
increased significantly in WT cells exposed to MI
(P ¼ .002 vs Tyrode’s) (Figure 2, B) and was inhibited by
the addition of glibenclamide (Figure 2, A).
WTmyocytes exposed to CPG alone after exposure to NT
exhibited no increase in sKATP current (Figure 3, A), and the
addition of DZX to CPG had no effect on the potassium cur-
rent when compared with CPG alone (Figure 3, A). The ad-
dition of pinacidil in cardioplegic solution was associated
with an increase in sKATP current, which returned to baseline
when cells were reexposed to NT (Figure 3, A, B). This in-
crease in potassium current was comparable to the potassium
current induced by MI.Myocyte Volume in Wild-Type and SUR1(-/-) Mice
WT and SUR1(-/-) myocytes exposed to NT had no sig-
nificant change in volume throughout the experimentgery c November 2010
FIGURE 4. DZX requires the SUR1 subunit of the KATP channel to main-
tain myocyte volume homeostasis in isolated ventricular myocytes. Myo-
cyte volume change is represented as relative percent increase in volume
for WT and SUR1(-/-) cells on the y axis. Myocytes were initially exposed
to NT for 5 minutes for baseline volume measurement. Myocytes were then
exposed to hyperkalemic CPG or hyperkalemic CPGþ100 mmol/L DZX.
WTmyocytes exposed to CPG significantly swelled, and this was prevented
by the addition of DZX (*P< .05 vs control and CPGþDZX). SUR1(-/-)
myocytes also significantly swelled when exposed to CPG (#P<.05 vs con-
trol), but the addition of DZXdid not prevent the swelling secondary to CPG
exposure (#P<.05 vs control). N¼ 8 cells for KO NT, N¼ 7 cells for KO
WT, N¼ 10 cells for KOCPG, N¼ 7 cells forWTCPG, N¼ 8 cells for KO
CPGþDZX, and N ¼ 7 cells for WT CPGþDZX.
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S(Figure 4). As demonstrated previously, exposure to hyper-
kalemic CPG resulted in significant (P<.05 vs control) WT
myocyte swelling (Figures 4 and 5), and DZX (100 mmol/L)
significantly ameliorated the volume change secondary to
CPG (P < .05). Although DZX is apparently without
effect on mouse ventricular myocytes, and ventricular
myocytes from SUR(-/-) animals contain normal sKATP
density,11 there was a marked loss of DZX action on cardi-
oplegic swelling in SUR(-/-) myocytes (Figures 4 and 5). As
discussed next, this result indicates that DZX is indeed
ameliorating cardioplegic swelling through the SUR1
subunit, but that this is independent of sKATP channels.
DISCUSSION
Diazoxide Is Not Associated With an Increase in
sKATP Channel Current in Wild-Type Ventricular
Myocytes
DZX did not induce an sKATP channel current in ventric-
ular myocytes alone or in the presence of hyperkalemic
CPG. These experiments indicate that under the observed
conditions, DZX (100 mmol/L) does not open the sKATP
channel in isolated mouse ventricular myocytes, consistent
with recent findings in mouse,11 rabbit,1 and rat ventricular
myocytes.19
Previous experiments documented significant (3.2%
from baseline) myocyte swelling secondary to hyperkalemic
CPG in myocytes isolated from mice lacking the Kir6.2
subunit of the sKATP channel.
3 This swelling was not alteredThe Journal of Thoracic and Carby the addition of DZX. Together with the findings of the
present study, these data could be consistent with an action
of DZX on a unique ventricular KATP channel composed of
Kir6.2/SUR1. Such a composition is clearly the major com-
position in pancreatic, neuronal, and mouse atrial cells,20 but
there is clear evidence that SUR2A, and not SUR1, is the
critical SUR subunit in generation of mouse ventricular
KATP.
11,21
Both Pinacidil and Metabolic Inhibition Produce an
Increase in sKATP Channel Current in Wild-Type
Myocytes
Pinacidil, a nonspecific KATP channel opener, was associ-
ated with a significant increase in sKATP channel current,
consistent with the findings of previous studies.22 MI is
known to induce a large sKATP channel current, and this is
consistent with the results of the present study.23
Mechanism of Myocyte Swelling Secondary to Stress
In the present study, the myocyte volume derangement af-
ter exposure to hyperkalemic CPG alone was evaluated as in
previous work.2 WT and SUR1(-/-) myocytes both demon-
strated a significant increase in size after exposure to hyper-
kalemic CPG (4%–7% increase in size vs baseline volume).
Similar volume derangements have been observed after mild
hyposmotic stress (6% increase in volume) andMI (10% in-
crease in volume).4,5 Each stress exposed the myocyte to
a unique osmotic challenge: hyperkalemic CPG exposed
the myocyte to a hyposmotic extracellular environment,
hyposmotic stress exposed the myocyte to a different
hyposmotic extracellular environment, and MI exposed the
myocyte to a hyperosmotic intracellular environment. The
KATP channel opener DZX prevented the volume
derangement in response to all 3 stresses independently.
The mechanism remains unknown; however, these data
suggest a role in cellular volume regulation.
Maintenance of Myocyte Volume Homeostasis by
Diazoxide Requires SUR1
Myocytes from mice lacking the SUR1 gene also swelled
significantly when exposed to CPG; however, DZX failed to
reverse the effect. This finding indicates that DZX is in fact
ameliorating cardioplegic swelling through the SUR1 sub-
unit, but that this is independent of sKATP channels. This rai-
ses the possibility that SUR1 is actually present in mouse
ventricle, but is not required for or part of the sKATP channel.
Location of Action of Diazoxide
The results of the present study suggest that the observed
protective mechanism of DZX in isolated myocytes (mainte-
nance of volume homeostasis and contractility during stress)
is dependent on the SUR1 subunit, but is independent of the
sKATP channel. The mechanism of action may be at the mito-
chondrial (mKATP) level or at a KATP channel-independentdiovascular Surgery c Volume 140, Number 5 1157
FIGURE 5. Representative isolated WT or SUR1 (-/-) myocytes at baseline volume and after exposure to test solution via inverted microscopy. Myocytes
were initially exposed to NT for 5 minutes for baseline volume measurement. Myocytes were then exposed to test solution (hyperkalemic CPG or hyperka-
lemic CPGþ100 mmol/L DZX). The red line drawn on the representative test cell represents the outline of that cell’s baseline volume. Significant volume
increase was noted in response to CPG in the WT and SUR (-/-) cells, and this was eliminated with the addition of DZX in the WT cells only.WT,Wild-type;
CPG, cardioplegia; DZX, diazoxide.
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Slocation in the ventricle. Many investigators attribute the
myocardial protection provided by KATP channel openers to
the opening of the purported mKATP channel rather than the
sKATP channel.
6,24,25 However, much of the data claimed as
support for the existence of an mKATP channel have been
indirect,26-28 including by measurement of mitochondrial
flavoprotein oxidation. Critics have noted that DZX inhibits
succinate dehydrogenase activity, which in turn will inhibit
the tricarboxylic acid cycle leading to oxidation of
mitochondrial flavoproteins.27 Other evidence supported by
patch clamping of the inner mitochondrial membrane docu-
menting the presence of mKATP channels has been criticized
because of its lack of reproducibility and potential contamina-
tion by other cellular membranes.7,27,29 The determination of
the structure of an mKATP channel would thus facilitate
localization of DZX’s mechanism of action.1158 The Journal of Thoracic and Cardiovascular SurRecent studies have documented RNA expression for
SUR1 in left ventricular tissue from failing human hearts.30
The elucidation of the composition of the KATP channel spe-
cifically in humans will also increase the knowledge of the
exact site of cardioprotection offered by DZX.
Study Limitations
This study investigated the action of DZX at the cellular
level and in one species. This species was chosen because
of the availability of a genetic knockout. Genetically tracta-
ble larger animal models are not available, and pharmaco-
logic methods have limitations as discussed. Potassium
current at the cellular level was measured to definitively ob-
serve any action of DZX at the sKATP channel in isolation.
Extrapolation to the whole organism level should therefore
be taken with caution.gery c November 2010
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SCONCLUSIONS
The inverse relationship previously demonstrated be-
tween myocyte volume derangement and contractility in iso-
lated myocytes suggested loss of myocyte volume
homeostasis as a potential mechanism of myocardial stun-
ning.4 The ability of DZX to prevent myocyte swelling
and resultant contractile dysfunction secondary to 3 inde-
pendent stresses in 3 species suggests that its use may be ex-
ploited for the reduction of myocardial stunning. Elucidation
of the mechanism of action of DZX in the mouse at the
cellular and subcellular levels will subsequently facilitate
its acceptance and use at the clinical level.
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Dr Friedhelm Beyersdorf (Freiburg, Germany). Swelling of
cardiomyocytes is an important aspect of ischemia–reperfusion in-
jury of the heart that leads to impaired myocardial function. You
simulate ischemia in your experiments by MI using a specific solu-
tion. I have 2 questions for you:
First, you showed that a current in the ATP-sensitive potassium
channels is not induced by CPG but by MI. However, both condi-
tions lead to cardiomyocyte swelling. In contrast, again, only swell-
ing caused by MI is prevented by DZX. Could you comment on
possible differences between these 2 experimental conditions?
Ms Sellitto. The hyperkalemic CPG is more of a hypo-osmotic
stress as opposed to the inhibition of metabolism. Possibly, because
it’s a different mechanism of action in the stresses, that would be the
difference in the activity of the sKATP channel.
Dr Beyersdorf. Second, Elrod and coworkers demonstrated in
an article in Circulation in 2008 that SUR1 KO mice are protected
against ischemia. Their experiments showed reduced infarct size
and preserved function after a surgical ligation of the left coronary
artery. Could you comment on a positive correlation between your
and their results?
Ms Sellitto. The SUR1 unit in the mouse model has been shown
to have heterozygotes found predominantly in the atria and not so
much in the ventricle. But in humans, SUR1 is more homogeneous,
so DZX could have an effect in preventing damage caused by ische-
mia in the human heart.diovascular Surgery c Volume 140, Number 5 1159
